Stock Chart

ROIV

$21.94 +1.48%
Score: 53.6 HOLD
LEAPs: SELL $25
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $25
Premium: $3.55
Expiry: Jan 15, 2027
Target: $27
Score: -44

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $23.28 - $23.96 STRONG_UPTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.88
Vol: 1.57x (vs SPY: 1.6x | vs QQQ: 1.7x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About ROIV - Roivant Sciences Ltd. Common Shares

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Key Statistics

Market Cap $15B

This ROIV stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track ROIV's price movements with trendlines, gamma walls, and key support/resistance levels.